United States Biotechnology & Medical Research

Immunome Inc (IMNM)

Track

Over the past 90 days, Immunome Inc. has seen significant insider selling activity, with 32 transactions totaling approximately $23 million in sales compared to $0.5 million in purchases. Key officers and shareholders, including ABHMC II, LLC and Isaac Barchas, have executed multiple planned and proposed sales as the stock price remains near its 52-week high.
Ticker: IMNM Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Immunome Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Proposed sale 6 Aug 2026
Value US$3,396,824.51 | Price 145.18 | Shares 40,070
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-08-06 2026-08-06 PrS Proposed sale
ABHMC II, LLC

Shareholder
40,070
145.18
US$3,396,825 		40,070 145.18 US$3,396,825
2026-08-06 2026-08-04 PlS Planned sale
1.6
Horn Kinney

CHIEF BUSINESS OFFICER

Officer
1,359 +38.9%
367.94
US$4,523,000 		1,359 +38.9% 367.94 US$4,523,000
2026-08-04 2026-08-04 PrS Proposed sale
1.6
Horn Kinney

Officer

Officer
84,075
378.89
US$4,140,265 		84,075 378.89 US$4,140,265
2026-07-09 2026-07-07 PlS Planned sale
1.6
Horn Kinney

CHIEF BUSINESS OFFICER

Officer
1,092 -100.0%
25.00
US$27,300 		1,092 -100.0% 25.00 US$27,300
2026-07-07 2026-07-07 PlS Planned sale
Barchas Isaac
Non-Executive Director
16,906 -13.5%
24.20
US$409,125 		16,906 -13.5% 24.20 US$409,125
2026-07-07 2026-07-07 PrS Proposed sale
1.6
Horn Kinney

Officer

Officer
1,092
25.00
US$27,300 		1,092 25.00 US$27,300
2026-07-07 2026-07-06 PlS Planned sale
Barchas Isaac
Non-Executive Director
83,094 -39.9%
24.11
US$2,003,396 		83,094 -39.9% 24.11 US$2,003,396
2026-07-06 2026-07-06 PrS Proposed sale
ABHMC II, LLC

Shareholder
100,000
23.61
US$2,361,000 		100,000 23.61 US$2,361,000
2026-07-07 2026-07-02 PlS Planned sale
2.2
Lechleider Robert

Chief Medical Officer

Officer
16,072 -50.4%
23.44
US$376,728 		16,072 -50.4% 23.44 US$376,728
2026-07-07 2026-07-02 PlS Planned sale
2.2
Lechleider Robert

Chief Medical Officer

Officer
16,214 -33.7%
22.76
US$369,031 		16,214 -33.7% 22.76 US$369,031
2026-07-07 2026-07-02 PlS Planned sale
2.2
Lechleider Robert

Chief Medical Officer

Officer
22,714 -32.1%
21.95
US$498,572 		22,714 -32.1% 21.95 US$498,572
2026-07-02 2026-07-02 PlS Planned sale
Barchas Isaac
Non-Executive Director
24,335 -10.5%
23.33
US$567,736 		24,335 -10.5% 23.33 US$567,736
2026-07-02 2026-07-02 PlS Planned sale
Barchas Isaac
Non-Executive Director
75,665 -24.5%
22.35
US$1,691,113 		75,665 -24.5% 22.35 US$1,691,113
2026-07-02 2026-07-02 PrS Proposed sale
ABHMC II, LLC

Shareholder
100,000
21.49
US$2,149,000 		100,000 21.49 US$2,149,000
2026-07-02 2026-07-02 PrS Proposed sale
2.2
Lechleider Robert

Officer

Officer
55,000
21.60
US$1,188,000 		55,000 21.60 US$1,188,000
2026-07-02 2026-06-30 PlS Planned sale
Barchas Isaac
Non-Executive Director
101,050 -24.7%
21.12
US$2,134,176 		101,050 -24.7% 21.12 US$2,134,176
2026-06-30 2026-06-30 PrS Proposed sale
Arsenal Bridge Venture II-B, LLC

Shareholder
1,050
21.04
US$22,092 		1,050 21.04 US$22,092
2026-06-30 2026-06-30 PrS Proposed sale
ABHMC II, LLC

Shareholder
100,000
21.04
US$2,104,000 		100,000 21.04 US$2,104,000
2026-06-29 2026-06-25 PlS Planned sale
2.2
Lechleider Robert

Chief Medical Officer

Officer
14,420 -47.7%
20.66
US$297,917 		14,420 -47.7% 20.66 US$297,917
2026-06-29 2026-06-25 PlS Planned sale
2.2
Lechleider Robert

Chief Medical Officer

Officer
40,580 -57.3%
19.56
US$793,745 		40,580 -57.3% 19.56 US$793,745
2026-06-25 2026-06-25 PrS Proposed sale
2.2
Lechleider Robert

Officer

Officer
55,000
19.73
US$1,085,150 		55,000 19.73 US$1,085,150
2026-06-17 2026-06-15 PlS Planned sale
3.3
Rosett Max

Chief Financial Officer

Officer
60,000 -52.6%
18.23
US$1,093,800 		60,000 -52.6% 18.23 US$1,093,800
2026-06-15 2026-06-15 PrS Proposed sale
3.3
Rosett Max

Officer

Officer
60,000
18.63
US$1,117,800 		60,000 18.63 US$1,117,800
2026-06-09 2026-06-05 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
1,000 +2.4%
19.27
US$19,270 		1,000 +2.4% 19.27 US$19,270
2026-06-09 2026-06-05 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
1,000 +2.4%
19.27
US$19,270 		1,000 +2.4% 19.27 US$19,270
2026-06-09 2026-06-05 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
3,500 +9.0%
19.46
US$68,110 		3,500 +9.0% 19.46 US$68,110
2026-06-09 2026-06-05 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
3,500 +9.0%
19.46
US$68,110 		3,500 +9.0% 19.46 US$68,110
2026-06-09 2026-06-05 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
6,000 +18.2%
19.48
US$116,880 		6,000 +18.2% 19.48 US$116,880
2026-06-09 2026-06-05 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
6,000 +18.2%
19.48
US$116,880 		6,000 +18.2% 19.48 US$116,880
2026-06-09 2026-06-05 S Sale
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
10,000 -23.3%
19.41
US$194,100 		10,000 -23.3% 19.41 US$194,100
2026-06-09 2026-06-05 S Sale
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
10,000 -23.3%
19.41
US$194,100 		10,000 -23.3% 19.41 US$194,100
2026-06-09 2026-06-05 S Sale
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
500 -1.2%
19.44
US$9,720 		500 -1.2% 19.44 US$9,720
2026-06-09 2026-06-05 S Sale
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
500 -1.2%
19.44
US$9,720 		500 -1.2% 19.44 US$9,720
2026-05-19 2026-05-15 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
5,000 +13.0%
20.70
US$103,500 		5,000 +13.0% 20.70 US$103,500
2026-04-03 2026-04-02 PlS Planned sale
2.2
Higgins Jack

Chief Scientific Officer

Officer
9,438 -30.0%
21.64
US$204,238 		9,438 -30.0% 21.64 US$204,238
2026-04-03 2026-04-02 PlS Planned sale
3.3
Rosett Max

Chief Financial Officer

Officer
1,344 -2.4%
22.48
US$30,213 		1,344 -2.4% 22.48 US$30,213
2026-04-03 2026-04-02 PlS Planned sale
3.3
Rosett Max

Chief Financial Officer

Officer
63,656 -53.5%
21.91
US$1,394,703 		63,656 -53.5% 21.91 US$1,394,703
2026-04-03 2026-04-02 PrS Proposed sale
3.3
Rosett Max

Officer

Officer
65,000
21.92
US$1,425,085 		65,000 21.92 US$1,425,085
2026-04-02 2026-04-02 PrS Proposed sale
3.3
Rosett Max

Officer

Officer
65,000
72.67
US$4,723,550 		65,000 72.67 US$4,723,550
2026-04-02 2026-04-02 PrS Proposed sale
2.2
Higgins Jack

Officer

Officer
9,438
21.64
US$204,238 		9,438 21.64 US$204,238
2026-03-31 2026-03-27 B Purchase
3.3
SIEGALL CLAY B

President and CEO

Executive Director
25,450 +3.8%
19.67
US$500,602 		25,450 +3.8% 19.67 US$500,602
2026-03-23 2026-03-23 S Sale
1.8
WAGENHEIM PHILIP
Non-Executive Director
28,200 -7.6%
20.65
US$582,330 		28,200 -7.6% 20.65 US$582,330
2026-03-23 2026-03-20 S Sale
1.8
WAGENHEIM PHILIP
Non-Executive Director
36,800 -9.1%
20.47
US$753,296 		36,800 -9.1% 20.47 US$753,296
2026-03-20 2026-03-20 PrS Proposed sale
1.8
WAGENHEIM PHILIP

Director

Non-Executive Director
65,000
20.81
US$1,352,640 		65,000 20.81 US$1,352,640
2026-03-12 2026-03-11 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
1,000 +2.7%
21.55
US$21,550 		1,000 +2.7% 21.55 US$21,550
2026-03-12 2026-03-10 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
1,000 +2.7%
22.12
US$22,120 		1,000 +2.7% 22.12 US$22,120
2025-12-30 2025-12-30 B Purchase
3.3
SIEGALL CLAY B

President and CEO

Executive Director
4,729 +0.7%
21.15
US$100,018 		4,729 +0.7% 21.15 US$100,018
2025-12-23 2025-12-22 PlS Planned sale
Barchas Isaac
Non-Executive Director
11,251 -0.6%
22.34
US$251,347 		11,251 -0.6% 22.34 US$251,347
2025-12-23 2025-12-22 PlS Planned sale
Barchas Isaac
Non-Executive Director
371,949 -15.4%
21.72
US$8,078,732 		371,949 -15.4% 21.72 US$8,078,732
2025-12-22 2025-12-19 B Purchase
3.3
SIEGALL CLAY B

President and CEO

Executive Director
7,278 +0.9%
20.48
US$149,053 		7,278 +0.9% 20.48 US$149,053
2025-12-22 2025-12-19 B Purchase
3.5
Tsai Philip

Chief Technical Officer

Officer
10,000 +30.0%
20.49
US$204,900 		10,000 +30.0% 20.49 US$204,900
2025-12-18 2025-12-18 B Purchase
3.3
SIEGALL CLAY B

President and CEO

Executive Director
46,511 +5.8%
21.50
US$999,986 		46,511 +5.8% 21.50 US$999,986
2025-06-03 2025-06-03 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
5,000 +15.9%
9.38
US$46,900 		5,000 +15.9% 9.38 US$46,900
2025-03-26 2025-03-26 B Purchase
3.3
SIEGALL CLAY B

President and CEO

Executive Director
137,100 +20.5%
7.29
US$999,459 		137,100 +20.5% 7.29 US$999,459
2025-03-26 2025-03-25 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
7,800 +33.0%
7.78
US$60,684 		7,800 +33.0% 7.78 US$60,684
2025-03-25 2025-03-24 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
7,000 +42.1%
8.21
US$57,470 		7,000 +42.1% 8.21 US$57,470
2025-03-25 2025-03-24 B Purchase
3.5
Tsai Philip

Chief Technology Officer

Officer
12,300 +58.6%
8.42
US$103,566 		12,300 +58.6% 8.42 US$103,566
2025-02-03 2025-01-31 B Purchase
3.3
SIEGALL CLAY B

President and CEO

Executive Director
150,000 +28.9%
7.75
US$1,162,500 		150,000 +28.9% 7.75 US$1,162,500
2024-11-25 2024-11-22 B Purchase
3.3
SIEGALL CLAY B

President and CEO

Executive Director
33,943 +7.0%
9.78
US$331,918 		33,943 +7.0% 9.78 US$331,918
2024-11-25 2024-11-21 B Purchase
3.3
SIEGALL CLAY B

President and CEO

Executive Director
66,057 +15.7%
9.54
US$630,263 		66,057 +15.7% 9.54 US$630,263
2024-11-25 2024-11-21 B Purchase
2.2
Lechleider Robert

Chief Medical Officer

Officer
15,805 +inf%
9.48
US$149,800 		15,805 +inf% 9.48 US$149,800
2024-11-25 2024-11-21 B Purchase
3.5
Tsai Philip

Chief Technology Officer

Officer
21,000 +inf%
9.43
US$198,030 		21,000 +inf% 9.43 US$198,030
2024-09-20 2024-09-19 S Sale
3.3
Rosett Max

Chief Financial Officer

Officer
14,380 -23.2%
16.01
US$230,224 		14,380 -23.2% 16.01 US$230,224
2024-09-19 2024-09-19 PrS Proposed sale
3.3
Rosett Max

Officer

Officer
14,380
16.01
US$230,211 		14,380 16.01 US$230,211
2024-08-19 2024-08-16 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
7,000 +72.8%
13.94
US$97,608 		7,000 +72.8% 13.94 US$97,608
2024-08-19 2024-08-15 S Sale
2.2
Higgins Jack

Chief Scientific Officer

Officer
3,524 -18.0%
13.93
US$49,072 		3,524 -18.0% 13.93 US$49,072
2024-08-15 2024-08-15 PrS Proposed sale
2.2
Higgins Jack

Officer

Officer
3,524
13.93
US$49,073 		3,524 13.93 US$49,073
2024-05-22 2024-05-21 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
2,000 +26.3%
13.57
US$27,140 		2,000 +26.3% 13.57 US$27,140
2024-05-21 2024-05-21 B Purchase
3.3
SIEGALL CLAY B

President and CEO

Executive Director
20,434 +5.1%
13.78
US$281,548 		20,434 +5.1% 13.78 US$281,548
2024-05-21 2024-05-20 B Purchase
3.3
SIEGALL CLAY B

President and CEO

Executive Director
79,566 +24.9%
13.91
US$1,106,524 		79,566 +24.9% 13.91 US$1,106,524
2023-10-04 2023-10-02 B Purchase
3.3
SIEGALL CLAY B

President and CEO

Executive Director
169,204 +112.5%
5.91
US$999,996 		169,204 +112.5% 5.91 US$999,996
2023-10-04 2023-10-02 B Purchase
Turner Bruce

Chief Strategy Officer

Officer
42,300 +inf%
5.91
US$249,993 		42,300 +inf% 5.91 US$249,993
2021-09-14 2021-09-13 B Purchase
2.4
RAPP MICHAEL
Non-Executive Director
25,962 +14.2%
19.96
US$518,202 		25,962 +14.2% 19.96 US$518,202
2021-09-13 2021-09-10 B Purchase
2.4
RAPP MICHAEL
Non-Executive Director
15,500 +9.3%
17.85
US$276,675 		15,500 +9.3% 17.85 US$276,675
2021-09-13 2021-09-09 B Purchase
2.4
RAPP MICHAEL
Non-Executive Director
22,280 +15.4%
18.46
US$411,289 		22,280 +15.4% 18.46 US$411,289
Explore more

More insider trading research around Immunome Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America